Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Current Leases: 2019-2025

Historic Current Leases for Ultragenyx Pharmaceutical (RARE) over the last 7 years, with Sep 2025 value amounting to $12.1 million.

  • Ultragenyx Pharmaceutical's Current Leases rose 16.48% to $12.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.1 million, marking a year-over-year increase of 16.48%. This contributed to the annual value of $10.3 million for FY2024, which is 18.25% down from last year.
  • According to the latest figures from Q3 2025, Ultragenyx Pharmaceutical's Current Leases is $12.1 million, which was up 3.20% from $11.8 million recorded in Q2 2025.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Current Leases peaked at $12.8 million during Q1 2024, and registered a low of $9.4 million during Q1 2021.
  • For the 3-year period, Ultragenyx Pharmaceutical's Current Leases averaged around $11.5 million, with its median value being $11.7 million (2024).
  • Its Current Leases has fluctuated over the past 5 years, first surged by 41.98% in 2021, then decreased by 18.25% in 2024.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Current Leases (Quarterly) stood at $11.1 million in 2021, then climbed by 6.44% to $11.8 million in 2022, then increased by 6.93% to $12.6 million in 2023, then decreased by 18.25% to $10.3 million in 2024, then grew by 16.48% to $12.1 million in 2025.
  • Its last three reported values are $12.1 million in Q3 2025, $11.8 million for Q2 2025, and $10.5 million during Q1 2025.